HomeESC 2025Coronary Disease

Coronary Disease

ESC 2025 | BETAMI-DANBLOCK: Randomized Discontinuation of Beta-Blockers after MI

The routine use of beta-blockers after acute myocardial infarction (AMI) has been a historical recommendation based on...

ESC 2025 | AMALFI: Remote Monitoring for Atrial Fibrillation Detection

Since atrial fibrillation (AF) may be asymptomatic and remain undiagnosed, the AMALFI study aimed to assess whether...

ESC 2025 | DANCAVAS 2: Cardiovascular Screening in Men Aged 60 to 64 Years

Cardiovascular diseases account for 31% of deaths in men under 70 years of age. In the DANCAVAS...

ESC 2025 | DUAL-ACS: Duration of Dual Antiplatelet Therapy in Acute Coronary Syndromes

The DUAL-ACS trial, a randomized multicenter study, was designed to evaluate whether a strategy of P2Y12 inhibitor...

ESC 2025 | OPTION-STEMI: Timing of Complete Revascularization During the Initial Hospitalization in Patients With ST-Segment Elevation Myocardial Infarction and Multivessel Disease

In patients with ST-segment elevation myocardial infarction (STEMI) and multivessel coronary artery disease (MVD), the optimal timing...

ESC 2025 | PULSE: Coronary CT Angiography vs Ischemia-Guided Follow-Up After Unprotected Left Main PCI

Courtesy of Dr. Juan Manuel Pérez. Unprotected left main (ULM) percutaneous coronary intervention (PCI) remains associated with a...